Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. - Related Studies

Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.

This study has been completed.

Study NCT00138983. Last updated on November 28, 2006. Information provided by UMC Utrecht

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Rheumatoid Arthritis
		Polymyalgia Rheumatica
		Giant Cell Arteritis
		Polymyositis
		Wegener’s Granulomatosis

2	Additional conditions recognized in this trial
		Arteritis
		Arthritis
		Arthritis, Rheumatoid
		Osteoporosis
		Rheumatic Diseases
		Wegener Granulomatosis

3	More general conditions related to this trial
		Autoimmune Diseases
		Autoimmune Diseases of the Nervous System
		Bone Diseases
		Bone Diseases, Metabolic
		Brain Diseases
		Cardiovascular Diseases
		Central Nervous System Diseases
		Cerebrovascular Disorders
		Connective Tissue Diseases
		Immune System Diseases
		Joint Diseases
		Kidney Diseases
		Lung Diseases
		Lung Diseases, Interstitial
		Muscular Diseases
		Musculoskeletal Diseases
		Myositis
		Nervous System Diseases
		Neuromuscular Diseases
		Respiratory Tract Diseases
		Skin Diseases
		Skin Diseases, Vascular
		Urologic Diseases
		Vascular Diseases
		Vasculitis
		Vasculitis, Central Nervous System

4	Additional drug interventions recognized in this trial
		1-hydroxycholecalciferol
		Alendronate
		Hydroxycholecalciferols

5	More general drug interventions related to this trial
		Bone Density Conservation Agents
		Growth Substances
		Micronutrients
		Pharmacologic Actions
		Physiological Effects of Drugs
		Vitamins

6	Sponsors listed in this trial
		UMC Utrecht
		Dutch Health Care Insurance Board